viewTiziana Life Sciences PLC

Tiziana's StemPrintER shown to be SUPERIOR to Exact Sciences' Oncotype DX breast cancer test

Tiziana Life Sciences (LON:TILS)(NASDAQ:TLSA) chairman Gabriele Cerrone speaks to Proactive's Andrew Scott after data on its StemPrintER breast cancer prognostic test was presented at the American Society of Clinical Oncology Virtual Conference.

He says the study demonstrated 'greater refinement and superiority of StemPrintER' over current market leader Oncotype DX in delivering prognostic information as part of the therapeutic decision-making process in ER+/HER2- breast cancer patients.

Cerrone says the findings are made all the more significant given the move last year by Exact Sciences (NASDAQ:EXAS) which paid $2.8bn to buy out Genomic Health because of its Oncotype DX technology.

Quick facts: Tiziana Life Sciences PLC

Price: 150 GBX

Market: AIM
Market Cap: £249.61 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Tiziana Life Sciences PLC named herein, including the promotion by the Company of Tiziana Life Sciences PLC in any Content on the Site, the...



Morning Report: FTSE 100 lower as US infections continue to rise

Headlines from the Proactive UK newsroom. The FTSE 100 headed lower in an uncertain start to the week as investors worried over the surge in US COVID-19 infections. The blue-chip index dipped 24 to 6,135. Deliveroo’s boss has warned that restaurants are 'hurting' due to the coronavirus...

2 weeks, 2 days ago

2 min read